Beyfortus (nirsevimab) - Sanofi
Fulminant necrotizing enterocolitis associated with severe RSV infection in a preterm infant following Nirsevimab prophylaxis: a case report. (PubMed, Neonatology) - Oct 25, 2026 - "Confirmation in additional clinical and translational studies is required. Further clinical and translational studies are required to clarify the potential role of RSV in intestinal disease and the mechanisms underlying severe breakthrough infections." 
Journal • Critical care • Gastrointestinal Disorder • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections
http://www.ncbi.nlm.nih.gov/pubmed/42912711
 
Céline Weber; Maya Caroline André; Philipp Meyer; Raphael N Vuille-Dit-Bille; Stefan Gerhard Holland-Cunz; Thomas Menter
 
Oct 25, 2026
 
Prev Next